Brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to post sales of $3.31 billion for the current quarter, according to Zacks. Nine analysts have issued estimates for Henry Schein’s earnings. The lowest sales estimate is $3.21 billion and the highest is $3.36 billion. Henry Schein posted sales of $3.12 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.1%. The company is scheduled to issue its next earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Henry Schein will report full-year sales of $3.31 billion for the current financial year, with estimates ranging from $12.29 billion to $12.54 billion. For the next fiscal year, analysts expect that the firm will post sales of $13.20 billion per share, with estimates ranging from $12.99 billion to $13.36 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Henry Schein.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). The company had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.84 earnings per share.

A number of research analysts recently issued reports on HSIC shares. Morgan Stanley downgraded Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price objective for the company. in a research note on Wednesday, December 6th. Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. Credit Suisse Group reissued a “neutral” rating and issued a $80.00 price target (down from $87.50) on shares of Henry Schein in a report on Tuesday, November 28th. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price target on shares of Henry Schein in a report on Wednesday, December 27th. Finally, Zacks Investment Research cut Henry Schein from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $84.23.

Henry Schein (NASDAQ:HSIC) opened at $76.35 on Thursday. The stock has a market capitalization of $11,934.81, a P/E ratio of 22.00, a P/E/G ratio of 1.94 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. Henry Schein has a 52 week low of $65.28 and a 52 week high of $93.50.

In other news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.19% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. YorkBridge Wealth Partners LLC raised its holdings in shares of Henry Schein by 5.2% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after acquiring an additional 28 shares in the last quarter. Sun Life Financial INC raised its holdings in shares of Henry Schein by 8,185.7% during the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after acquiring an additional 573 shares in the last quarter. Cypress Capital Management LLC purchased a new stake in shares of Henry Schein during the 2nd quarter worth approximately $217,000. FTB Advisors Inc. raised its holdings in shares of Henry Schein by 100.0% during the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock worth $120,000 after acquiring an additional 742 shares in the last quarter. Finally, Trust Co. of Vermont raised its holdings in shares of Henry Schein by 56.7% during the 3rd quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock worth $140,000 after acquiring an additional 616 shares in the last quarter. 91.70% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/18/henry-schein-inc-hsic-expected-to-announce-quarterly-sales-of-3-31-billion.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.